- $31.67m
- $24.20m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 6.79 | ||
| Price to Tang. Book | 6.79 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -312.36% | ||
| Return on Equity | -243.33% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Acurx Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a new class of small molecule antibiotics for difficult-to-treat bacterial infections. It develops antibiotic candidates with a Gram-positive selective spectrum (GPSS) that block the active site of the Gram positive specific bacterial enzyme deoxyribonucleic acid (DNA) polymerase IIIC (pol IIIC), inhibiting DNA replication and leading to Gram-positive bacterial cell death. Its research and development (R&D) pipeline include antibiotic product candidates that target Gram-positive bacteria, including Clostridioides difficile (C. difficile), methicillin-resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococcus (VRE) and drug-resistant Streptococcus pneumoniae (DRSP). Its lead antibiotic candidate, ibezapolstat targets the pol IIIC enzyme. Phase II clinical data validate the efficacy of its lead antibiotic candidate, as well as pol IIIC as an appropriate bacterial target.
Directors
- Last Annual
- December 31st, 2023
- Last Interim
- December 31st, 2023
- Incorporated
- July 19th, 2017
- Public Since
- June 25th, 2021
- No. of Shareholders
- 362
- No. of Employees
- 4
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Capital Market- Shares in Issue
- 15,757,102
- Address
- 259 Liberty Avenue, STATEN ISLAND, 10305
- Web
- https://www.acurxpharma.com/
- Phone
- +1 9175331469
- Auditors
- CohnReznick LLP
Upcoming Events for ACXP
Q1 2024 Acurx Pharmaceuticals Inc Earnings Release
Acurx Pharmaceuticals Inc Annual Shareholders Meeting
Acurx Pharmaceuticals Inc Annual Shareholders Meeting
Q2 2024 Acurx Pharmaceuticals Inc Earnings Release
Q2 2024 Acurx Pharmaceuticals Inc Earnings Release
Similar to ACXP
180 Life Sciences
NASDAQ Capital Market
Abeona Therapeutics
NASDAQ Capital Market
ABVC Biopharma
NASDAQ Capital Market
Acesis Holdings
NASDAQ Capital Market
Achieve Life Sciences
NASDAQ Capital Market
FAQ
What is the Acurx Pharmaceuticals share price?
As of Today at 19:00 UTC, shares in Acurx Pharmaceuticals are trading at $2.01. This share price information is delayed by 15 minutes.
How has the Acurx Pharmaceuticals share price performed this year?
Shares in Acurx Pharmaceuticals last closed at $2.01 and the price had moved by -34.95% over the past 365 days. In terms of relative price strength the Acurx Pharmaceuticals share price has underperformed the S&P500 Index by -45.87% over the past year.
What are the analyst and broker recommendations for Acurx Pharmaceuticals?
The overall consensus recommendation for Acurx Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the Acurx Pharmaceuticals dividend yield?
Acurx Pharmaceuticals does not currently pay a dividend.
Does Acurx Pharmaceuticals pay a dividend?
Acurx Pharmaceuticals does not currently pay a dividend.
When does Acurx Pharmaceuticals next pay dividends?
Acurx Pharmaceuticals does not currently pay a dividend.
How do I buy Acurx Pharmaceuticals shares?
To buy shares in Acurx Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Acurx Pharmaceuticals?
As of the previous close price of $2.01, shares in Acurx Pharmaceuticals had a market capitalisation of $31.67m.
Where are Acurx Pharmaceuticals shares listed?
Here are the trading details for Acurx Pharmaceuticals:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ACXP
What kind of share is Acurx Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum Acurx Pharmaceuticals is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Acurx Pharmaceuticals share price forecast for 2024?
The analyst consensus target price for shares in Acurx Pharmaceuticals is $12.09. That is 501.49% above the last closing price of $2.01.
Analysts covering Acurx Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$0.97 for the next financial year.
What is the trend in the Acurx Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Acurx Pharmaceuticals. Over the past six months, its share price has underperformed the S&P500 Index by -67.06%.
As of the last closing price of $2.01, shares in Acurx Pharmaceuticals were trading -30.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Acurx Pharmaceuticals PE Ratio?
The Acurx Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $2.01.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Acurx Pharmaceuticals?
We do not have data on Acurx Pharmaceuticals' directors